110 research outputs found
An analytical upper bound on the number of loci required for all splits of a species tree to appear in a set of gene trees
Policy challenges for the pediatric rheumatology workforce: Part I. Education and economics
For children with rheumatic conditions, the available pediatric rheumatology workforce mitigates their access to care. While the subspecialty experiences steady growth, a critical workforce shortage constrains access. This three-part review proposes both national and international interim policy solutions for the multiple causes of the existing unacceptable shortfall. Part I explores the impact of current educational deficits and economic obstacles which constrain appropriate access to care. Proposed policy solutions follow each identified barrier
A Small-Molecule Inhibitor of T. gondii Motility Induces the Posttranslational Modification of Myosin Light Chain-1 and Inhibits Myosin Motor Activity
Toxoplasma gondii is an obligate intracellular parasite that enters cells by a process of active penetration. Host cell penetration and parasite motility are driven by a myosin motor complex consisting of four known proteins: TgMyoA, an unconventional Class XIV myosin; TgMLC1, a myosin light chain; and two membrane-associated proteins, TgGAP45 and TgGAP50. Little is known about how the activity of the myosin motor complex is regulated. Here, we show that treatment of parasites with a recently identified small-molecule inhibitor of invasion and motility results in a rapid and irreversible change in the electrophoretic mobility of TgMLC1. While the precise nature of the TgMLC1 modification has not yet been established, it was mapped to the peptide Val46-Arg59. To determine if the TgMLC1 modification is responsible for the motility defect observed in parasites after compound treatment, the activity of myosin motor complexes from control and compound-treated parasites was compared in an in vitro motility assay. TgMyoA motor complexes containing the modified TgMLC1 showed significantly decreased motor activity compared to control complexes. This change in motor activity likely accounts for the motility defects seen in the parasites after compound treatment and provides the first evidence, in any species, that the mechanical activity of Class XIV myosins can be modulated by posttranslational modifications to their associated light chains
Policy challenges for the pediatric rheumatology workforce: Part II. Health care system delivery and workforce supply
The United States pediatric population with chronic health conditions is expanding. Currently, this demographic comprises 12-18% of the American child and youth population. Affected children often receive fragmented, uncoordinated care. Overall, the American health care delivery system produces modest outcomes for this population. Poor, uninsured and minority children may be at increased risk for inferior coordination of services. Further, the United States health care delivery system is primarily organized for the diagnosis and treatment of acute conditions. For pediatric patients with chronic health conditions, the typical acute problem-oriented visit actually serves as a barrier to care. The biomedical model of patient education prevails, characterized by unilateral transfer of medical information. However, the evidence basis for improvement in disease outcomes supports the use of the chronic care model, initially proposed by Dr. Edward Wagner. Six inter-related elements distinguish the success of the chronic care model, which include self-management support and care coordination by a prepared, proactive team
Antimalarial drug targets in Plasmodium falciparum predicted by stage-specific metabolic network analysis
Multi-ancestry genome-wide association meta-analysis of Parkinson’s disease
\ua9 2023, This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply. Although over 90 independent risk variants have been identified for Parkinson’s disease using genome-wide association studies, most studies have been performed in just one population at a time. Here we performed a large-scale multi-ancestry meta-analysis of Parkinson’s disease with 49,049 cases, 18,785 proxy cases and 2,458,063 controls including individuals of European, East Asian, Latin American and African ancestry. In a meta-analysis, we identified 78 independent genome-wide significant loci, including 12 potentially novel loci (MTF2, PIK3CA, ADD1, SYBU, IRS2, USP8, PIGL, FASN, MYLK2, USP25, EP300 and PPP6R2) and fine-mapped 6 putative causal variants at 6 known PD loci. By combining our results with publicly available eQTL data, we identified 25 putative risk genes in these novel loci whose expression is associated with PD risk. This work lays the groundwork for future efforts aimed at identifying PD loci in non-European populations
Genetic determinants of daytime napping and effects on cardiometabolic health
This is the final version. Available from Nature Research via the DOI in this record. Summary GWAS statistics are publicly available at The Sleep Disorder Knowledge Portal
webpage: http://sleepdisordergenetics.org/.Daytime napping is a common, heritable behavior, but its genetic basis and causal relationship with cardiometabolic health remain unclear. Here, we perform a genome-wide association study of self-reported daytime napping in the UK Biobank (n = 452,633) and identify 123 loci of which 61 replicate in the 23andMe research cohort (n = 541,333). Findings include missense variants in established drug targets for sleep disorders (HCRTR1, HCRTR2), genes with roles in arousal (TRPC6, PNOC), and genes suggesting an obesity-hypersomnolence pathway (PNOC, PATJ). Association signals are concordant with accelerometer-measured daytime inactivity duration and 33 loci colocalize with loci for other sleep phenotypes. Cluster analysis identifies three distinct clusters of nap-promoting mechanisms with heterogeneous associations with cardiometabolic outcomes. Mendelian randomization shows potential causal links between more frequent daytime napping and higher blood pressure and waist circumference.National Institute of HealthNational Institute of HealthNational Institute of HealthNational Institute of HealthNational Institute of HealthMGH Research Scholar Fund, Academy of FinlandMedical Research CouncilSpanish Government of Investigation, Development and InnovationSeneca FoundationNIDDKInstrumentarium Science FoundationYrjö Jahnsson Foundatio
The Parkinson’s Disease Mendelian Randomization Research Portal
Mendelian randomization is
a method for exploring observational associations to find
evidence of causality. To apply Mendelian randomization between
risk factors/phenotypic traits (exposures) and PD in a
large, unbiased manner, and to create a public resource
for research. We observed evidence for causal associations
between 12 exposures and risk of PD. Of these, nine
were effects related to increasing adiposity and
decreasing risk of PD. The remaining top three exposures
that affected PD risk were tea drinking, time spent
watching television, and forced vital capacity, but these
may have been biased and were less convincing. Other
exposures at nominal statistical significance included
inverse effects of smoking and alcohol. We present a new platform which offers
Mendelian randomization analyses for a total of 5,839
genome-wide association studies versus the largest
PD genome-wide association studies available
(https://pdgenetics.shinyapps.io/MRportal/). Alongside,
we report further evidence to support a causal
role for adiposity on lowering the risk of PD. © 2019
The Authors. Movement Disorders published by Wiley
Periodicals, Inc. on behalf of International Parkinson
and Movement Disorder Society.AJN reports grants from Parkinson’s UK, Barts Charity, Leonard Wolfson Experimental Neurology Centre, UCL
Movement Disorders Centre and the Virginia Kieley Benefaction; honoraria or consultancy fees from Britannia,
Global Kinetics Corporation, Profile Pharmaceuticals, Guide point, Biogen and Roche. KH and DAH are employees
of 23andMe and hold stock or stock options in 23andMe. DAL reports grants from the Medical Research Council,
numerous charitable funders,Medtronic and Roche. ZG-O reports consultancy fees from Inceptions Sciences,Idorsia,
Denali, Lysosomal Therapeutics inc. HM reports reports consultancy from Biogen, UCB, Abbvie, Denali, Biohaven;
lecture fees/honoraria from Biogen, UCB,C4X Discovery, GE-Healthcare, Welcome Trust, Movement Disorders Society;
Research Grants from Parkinson’s UK, Cure Parkinson’s Trust, PSP Association, CBD Solutions, Drake Foundation,
Medical Research Council. Dr Morris is a co-applicanton a patent application related to C9ORF72
(PCT/GB2012/052140)
Radiosynthesis and first preclinical evaluation of the novel norepinephrine transporter pet-ligand [11C]ME@HAPTHI
- …